A double-blind placebo controlled randomized phase III trial of Fulvestrant and Ipatasertib as treatment for advanced HER-2 Negative and Estrogen Receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor